Cutaneous malignant melanoma results from the interplay of genetic, host, and environmental factors. Genetic factors implicated in melanoma etiology include inherited high-, intermediate-, and low-risk susceptibility genes as well as numerous somatic mutations in melanoma tumors. CDKN2A is the major high-risk melanoma susceptibility gene identified to date. Recent identification of low-risk loci has been accomplished predominantly through genome-wide association studies. Whole-exome and whole-genome studies have identified numerous genes somatically altered in melanoma tumors and highlighted a higher mutation load in melanoma tumors compared with those in other cancers. This higher load is believed to be attributable to the preponderance of cytosine-to-thymine nucleotide substitutions as a result of UV radiation exposure. Technological advances, particularly nextgeneration sequencing, have increased the opportunities for germline and somatic gene discovery in melanoma and are opening up new avenues for understanding melanoma pathogenesis as well as leading to new opportunities for treatment.
ARF ) was not significant. Similarly, no significant association was found between NSTs and any CDKN2A mutation (49) . Given the low frequency of ARF mutations overall (approximately 2.5% in the large GenoMEL sample), very large studies will be needed to fully examine the connections between NSTs and mutations that alter the p14 ARF protein. Other cancers have also been inconsistently reported as associated with CDKN2A mutations. For example, breast cancer was shown to be associated with Swedish melanoma-prone families with CDKN2A mutations who predominantly have the Swedish founder mutation (15) , but this association was not observed in other populations (38, 52, 54) . Whether these inconsistencies reflect different genetic backgrounds, modifying genetic and/or environmental factors, chance findings, or limited power remains to be determined. Similar to the work in pancreatic cancer and NSTs, evaluation of other cancers in families with CDKN2A mutations will require very large sample sizes. Furthermore, most studies examining the risks of other cancers have not been population based, and therefore the selection methods used to ascertain patients/families might have influenced the associations observed. Specifically, cancer risks may be biased if cancers that occurred prior to the ascertainment of the families influenced the participation/selection of the families in the research study and such cancer occurrences were included in the risk evaluation (54) . If possible, future studies of cancer risks should be population based; if that is not possible, then evaluation of risks of other cancers should be restricted to the period after the families are ascertained (i.e., the prospective period) to minimize selection bias.
CDKN2A and modifying factors. Although CDKN2A mutations confer substantial risk for melanoma, other host, genetic, and environmental factors further enhance risk (13, 24, 25, 51) . Identification of these factors should help reduce melanoma risk in susceptible subjects and families with mutations as well as increase understanding of disease processes. Studies of melanoma-prone families with CDKN2A mutations have identified atypical/dysplastic nevi, increased numbers of typical nevi, and poor tanning ability and/or propensity to sunburn as host modifying factors (24, 25, 51) . UV radiation has also inconsistently been shown to modify melanoma risk in families with CDKN2A mutations (13, 32) . Finally, melanocortin 1 receptor (MC1R) variants have consistently been shown to enhance melanoma risk in patients with CDKN2A mutations (37, 64) . In the largest study conducted to date, GenoMEL evaluated MC1R variants in 815 CDKN2A mutation carriers (473 affected, 372 unaffected) from 186 GenoMEL families (37) . The presence of one MC1R variant was associated with a twofold-increased risk for melanoma; the presence of two or more MC1R variants was associated with an almost sixfold-increased risk for melanoma. Analysis of MC1R variants and hair color, number of nevi, and propensity to sunburn showed that MC1R variants, blond/red hair color, and an increased number of nevi were jointly associated with melanoma risk (37) . Several studies are currently under way to identify additional host, genetic, and environmental risk factors; quantify the associated risks; and evaluate interactions with CDKN2A mutations. The major challenge for these studies is the sample sizes required to have sufficient power to identify the modifying factors and interactions.
CDK4.
The CDK4 gene is located on chromosomal region 12q14; it acts as an oncogene and is resistant to the normal physiological inhibition of p16 (146) . Like mutations in CDKN2A, mutations in CDK4 confer substantial risk for melanoma when found in melanoma-prone families. CDK4 mutations are extremely rare, however, and have been reported in fewer than 20 families worldwide (89, 106, 114, 124, 153) . To date, all cosegregating disease-related CDK4 germline mutations have been identified in exon 2, a region that codes for the p16 binding site. The two wellcharacterized causal CDK4 mutations are p.R24C and p.R24H. In the large mutation prevalence family study conducted by GenoMEL, CDK4 mutations were observed in only approximately 2% of families (49) . Mutations in CDK4 are thus likely to be almost undetectable in the general population of melanoma patients.
BAP1
. BAP1 is a tumor suppressor gene located on chromosomal region 3p21. Germline mutations in BAP1 were recently reported in several families with malignant mesothelioma, atypical melanocytic tumors, and other neoplasms (1, 20, 63, 94, 130, 138, 144, 145) . The predominant tumor types observed across the families with these mutations included mesothelioma, uveal melanoma, cutaneous melanoma, and melanocytic tumors, which ranged histopathologically from epithelioid nevi to atypical melanocytic proliferations that had features that overlapped with those of cutaneous melanoma (145) . To date, approximately 75% of reported families with germline BAP1 mutations have had at least one patient with cutaneous melanoma, suggesting that BAP1 should be considered a rare high-risk melanoma susceptibility gene (1, 20, 63, 94, 130, 138, 144, 145) . Furthermore, Njauw et al. (94) analyzed 200 hereditary cutaneous melanoma patients and found BAP1 germline mutations in 2 of 7 cutaneous melanoma probands from families with both cutaneous and ocular melanoma and in 1 of 193 cutaneous melanoma probands from families with only cutaneous melanoma (i.e., no ocular melanoma) (29% versus 0.52%; p = 0.003). Thus, BAP1 mutations appear to be associated with cutaneous melanoma primarily in conjunction with uveal melanoma. Future studies will be required to determine the full spectrum of tumor types, frequencies, and risks associated with BAP1 mutations. Current data suggest that, similar to germline CDK4 mutations, germline BAP1 mutations will be almost undetectable in the general population of melanoma patients.
Intermediate-and Low-Risk Melanoma Susceptibility Genes
Diseases with complex origins, like melanoma, result from a combination of genetic and environmental factors and the interactions between these factors. The study of such diseases involves many approaches to identify the genetic and environmental contributions to disease risk. Depending on the frequencies and the expected effect sizes of the various components, different study designsfrom family-based studies to genome-wide association studies (GWAS) using case-control or cohort data-are needed to uncover the genetic susceptibility variants. Although multiple high-risk melanoma susceptibility genes have been identified and are critical for understanding melanoma biology and pathogenesis, the frequencies of alterations in these genes are very low in the general population of melanoma patients. These genes, therefore, explain little of the genetic risk for melanoma. As such, alternative approaches have been used to try to identify more of the germline genetic risks for melanoma.
As with most complex diseases, recent successes in genetic variant identification for melanoma have focused on GWAS and the detection of common, low-risk susceptibility gene variants. Several GWAS of melanoma have been conducted, resulting in the identification of more than 15 loci that are directly or indirectly associated with melanoma risk. Table 1 summarizes the chromosomal regions, candidate genes, association with nevus and pigmentation phenotypes, and selected references for loci identified from studies of melanoma patients and controls.
The early case-control study searches for common susceptibility gene variants focused on candidate genes in the major phenotype-associated pathways in melanoma etiology, such as nevogenesis and pigmentation (see Table 1 and References 23, 47, and 80). Although variants in genes such as MC1R, SLC45A2, OCA2, and ASIP were identified using these strategies, recent GWAS have identified many additional gene variants that are directly associated with melanoma or indirectly associated with melanoma through nevus or pigmentation phenotypes. In fact, most of the initial variants associated with melanoma were in chromosomal regions containing nevusor pigmentation-related genes (CDKN2A/MTAP, PLA2G6, and TERT-CLPTM1L for nevi, and ASIP, IRF4, MC1R, OCA2, SLC45A2, TYR, and TYRP1 for pigmentation) (see Table 1 ). Since 2011, however, several additional loci that are not related to the major phenotypeassociated risk factors for melanoma have been identified. The newly identified variants included a single-nucleotide polymorphism (SNP) in ATM at 11q22.3 (rs1801516; p = 3.4 × 10 −9 ), a SNP in MX2 at 21q22.3 (rs45430; p = 2.9 × 10 −9 ), a SNP in the promoter of PARP1 at 1q42 (rs3219090; p = 9.3 × 10 −8 ), a SNP adjacent to CASP8 at 2q33.1 (rs13016963; p = 8.6 × 10 −10 ), and a region containing many genes at 1q21 (top SNP rs7412746; p = 9.0 × 10 −11 ) (3, 6, 86, 151) . Because of its relationship to CDKN2A, another locus near CCND1 (rs1485993; p = 4.6 × 10 −7 ) remains of potential interest, with suggestive but inconclusive evidence of replication (6) . Most of the effect sizes for the various SNPs ranged from ∼0.80-0.90 for SNPs that appeared protective against melanoma to ∼1.1-1.3 for SNPs that increased risk for melanoma (80) . Based on the discovery samples from recent GWAS, more loci with similar effect sizes may be identified as GWAS power increases (6) . Finally, the identification of genes outside the nevus and pigmentation phenotype pathways opens up potential new directions for melanoma research (6, 80) .
MC1R.
The best characterized of the low-risk susceptibility genes is MC1R, which is involved in normal pigment variation in humans (17, 117) . MC1R is highly polymorphic in Caucasian populations, and many variants have altered function (46, 73, 74, 117) . Five variants (p.D84E, p.R142H, p.R151C, p.R160W, and p.D294H) have been designated as RHC (red hair color) or R variants, and some are associated with poor tanning ability, extensive freckling, and fair skin color. Most other variants, designated non-RHC or r variants, have a weaker or no association with red hair color, although there is some variation across study populations (44, 73, 104, 116, 128) .
Numerous studies have shown an increased risk of melanoma among MC1R carriers. In general, risks were increased approximately 1.5-fold for carriers of one MC1R variant, with the strongest effects (2-7-fold-increased risk) observed for carriers of multiple variants, particularly R variants (23, 46, 73, 116) . Risk estimates for melanoma and pigmentation phenotypes for specific variants or populations have varied widely, suggesting that MC1R variants could play a role in melanoma development through both pigmentation and nonpigmentation pathways. In addition, differences in phenotype distributions, UV exposure, allele frequencies, and genetic background across populations might contribute to variation in melanoma risk associated with MC1R (73, 74, 116, 117, 147) . Given the effect estimates associated with multiple R variants, MC1R should be classified as both an intermediate-and low-risk melanoma susceptibility gene. Gaining a better understanding of the relationship between MC1R and melanoma will require large study samples from populations with a wide range of pigmentary, host, and exposure characteristics.
MITF.
Microphthalmia-associated transcription factor (MITF) is an oncogene located at chromosomal region 3p14. MITF regulates genes involved in cell cycle control and melanogenesis (26, 80) . Somatic alterations of MITF in melanoma tumors have been well established (see Somatic Alterations, below). Recently, a rare germline mutation of MITF that resulted in a glutamic-acidto-lysine change at codon 318 (p.E318K) was shown to be associated with both melanoma and renal cancer (11, 150) . Thus, MITF was determined to be an intermediate-risk melanoma susceptibility gene. The two studies used different approaches to identify this substitution, illustrating expanded opportunities for the discovery of additional intermediate-risk susceptibility genes.
Bertolotto et al. (11) used a candidate-gene strategy to investigate genes that might underlie the joint genetic predisposition related to melanoma and renal cell carcinoma (RCC) coexisting in the same patients. MITF was an attractive candidate because of its involvement in melanogenesis; it also stimulates the transcription of the alpha subunit of hypoxia-inducible factor 1 (HIF1A), the pathway targeted by renal cancer susceptibility genes. Sequencing of MITF in 62 patients with melanoma and RCC led to the identification of p.E318K in five patients. This missense substitution occurred at a significantly higher frequency in genetically enriched patients affected with melanoma, RCC, or both cancers (frequency 0.016) compared with controls (frequency 0.003). Carriers of p.E318K with melanoma and/or RCC had a more than 5-fold-increased risk for their respective cancers compared with controls; those with both melanoma and RCC had a 14-fold-increased risk for cancer (11) .
Yokoyama et al. (150) conducted whole-genome sequencing in probands from several melanoma-prone families and identified one proband who carried the then-novel p.E318K variant in MITF. Although the variant did not completely cosegregate with melanoma in the family in which it was observed, linkage analysis of 31 families suggested that it might be an intermediaterisk variant. Subsequent examination of independent case-control samples from Australia and the United Kingdom showed that the p.E318K variant was significantly associated with melanoma risk, with an overall more than twofold-increased risk. In the Australian sample, the variant was also associated with increased nevus count and nonblue eye color. Similar to the results of Bertolotto et al. (11) , the risk associated with p.E318K was higher for patients with an increased genetic load (e.g., positive family history of melanoma or multiple primary melanomas), with a greater than eightfoldincreased risk in patients with multiple melanomas and a family history of melanoma (150) .
The variant identified by Bertolotto et al. (11) and Yokoyama et al. (150) occurred in codon 318, located in a small ubiquitin-like modifier (SUMO) consensus site, and the variant severely impaired SUMOylation of MITF. The variant enhanced MITF protein binding to the HIF1A promoter and increased its transcriptional activity compared with the wild type. The variant also differentially regulated several MITF targets and showed changes consistent with a gain-of-function role in tumorigenesis. Overall, the findings showed that MITF is a melanoma susceptibility gene, with p.E318K classified as an intermediate-risk variant. Case-control, family, and functional studies are ongoing to examine additional MITF variants and determine whether they increase risk for melanoma, renal cancer, or other cancers.
Future Searches for Melanoma Susceptibility Genes
Although many low-risk genes and several intermediate-or high-risk genes for melanoma have been identified, much of the genetic risk has still not been explained (23, 80) . This situation may reflect further complexities as well as the interplay between host, genetic, and environmental risk factors that have not yet been adequately studied.
Mutations in the known high-risk melanoma genes account for melanoma susceptibility in approximately 20-40% of melanoma-prone families, suggesting the existence of additional high-risk susceptibility genes. Linkage analyses have mapped several additional melanoma loci to chromosomal regions 1p22, 1p36, and 9q21 (5, 19, 48, 72) , but so far germline mutations in candidate genes in these regions have not been detected. Identifying additional high-risk melanoma susceptibility genes has been challenging because of the presence of genetic heterogeneity, the potential rarity of mutations such as those observed for CDK4 and BAP1, and the complexity of the underlying genetic susceptibility. In addition, although some mutation-negative families have many melanoma cases, many families have only two or three available melanoma patients; thus, studies may lack the power to identify high-risk susceptibility genes, particularly given the likely genetic heterogeneity.
Improvements and advances in technology are expanding the approaches available for identifying germline alterations and explaining more of the genetic risk for melanoma. For example, next-generation sequencing offers an important advance in the approaches available for identifying susceptibility genes. There is great optimism within the genetics community that wholeexome/whole-genome sequencing will lead to new discoveries of disease susceptibility gene variants for many cancers where susceptibility appears to have a Mendelian component. Combining next-generation sequencing with high-quality clinical and epidemiological data and moleculargenetics/functional-genomics/bioinformatics data should enhance the prospects for finding new melanoma susceptibility gene variants.
Recent discoveries are opening up new avenues for understanding melanoma pathogenesis as well as leading to new opportunities for treatment. As power increases and studies become better able to address the many challenges involved in gene discovery, there will be more opportunities to improve our understanding of melanoma genetics.
SOMATIC ALTERATIONS
In addition to the germline alterations described above, a plethora of somatic alterations can occur in numerous genetic loci. Recent exome-and genome-wide studies have highlighted a higher mutation load in melanoma compared with other cancers (Figure 1) , which is believed to be attributable largely to the preponderance of cytosine-to-thymine nucleotide substitutions as a result of UV exposure (92, 107, 143) . This high somatic mutation rate necessitates a distinction between driver and passenger mutations; driver mutations are considered to have a pathological role in disease, whereas passenger mutations, although occurring during the tumorigenic process, do not confer any advantage to the tumor cell. A higher-than-expected ratio of nonsynonymous to synonymous mutations in a particular gene, recurrence of the same mutation in multiple individuals, bioinformatic assessment of mutation effects in relation to protein function or evolutionary conservation, and biological/biochemical assessment of mutations in model systems can all provide good indications of whether mutations are likely to behave as drivers in melanomagenesis. Before the advent of next-generation sequencing technologies, the majority of somatically altered genes in melanoma were identified through candidate-gene approaches.
The RAS-RAF-MEK-ERK-MAPK Pathway
By prioritizing analysis of the most likely pathways, initial studies were able to identify two of the most frequently somatically mutated genes in melanoma found to date: BRAF and N-RAS.
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Candidate-gene screening of the RAS-RAF-MEK-ERK-MAPK pathway, activation of which promotes cell proliferation, survival, differentiation, apoptosis, motility, and metabolism (76), identified several BRAF mutations across numerous cancer types. The most striking results were found in melanoma, where 35 of the 58 melanoma samples screened possessed an identical BRAF mutation, accounting for 92% of all of the BRAF mutations found in melanoma (34) . The high frequency of BRAF mutations has been validated in numerous follow-up studies, with the ultimate finding that BRAF mutations occur in 50-60% of all cutaneous malignant melanomas (34, 87) . This mutation, a valine-to-glutamate change at residue 600 (p.V600E), activates the MAPK pathway and stimulates endogenous ERK1/2 phosphorylation more strongly than wild-type BRAF does. In culture, the mutation stimulated foci formation more than 100 times more efficiently than wild-type BRAF did (34) . The mutation lies adjacent to T598 and S601, both of which are phosphorylated in the active form of BRAF. The insertion of a negatively charged residue is believed to mimic the phosphorylation seen in its active form (34) . Importantly, the p.V600E change has been observed at a high frequency in early melanocytic nevi, suggesting that it is an early somatic event likely to be associated with melanoma initiation (79, 109) . Additionally, this mutation was maintained between primary and metastatic tumors, demonstrating the selection of this mutation and the clonal origin of the metastases (97) . Given the extremely high frequency of BRAF alterations in melanoma and its tumor-driving properties, selective BRAF inhibitors have now been developed, two of which-vemurafenib (formerly PLX4032) and dabrafenib (formerly GSK2118436)-have had success in clinical trials and are currently being used to treat patients affected by the p.V600E mutation (reviewed in 43). NRAS is a member of the RAS GTPase family of proteins, which typically reside at the cellular membrane and, when stimulated by their respective receptors, cycle from their inactive GDP-bound state to their active GTP-bound state (76) . In their GTP-bound conformation, RAS proteins recruit various RAF proteins to the cellular membrane, where they are phosphorylated and activated and then phosphorylate other messengers in the MAPK pathway (95) . Indeed, Ras genes, which include several isoforms, are frequently mutated in human cancers (62) . In melanoma, mutations are found almost exclusively in the NRas gene. The majority of these mutations fall at codon 12, 13, or 61 (8) ; 90% occur at codon 61, an asparagine (N61) that is commonly mutated to either a glutamine or a lysine (62) . This NRas N61 mutation is found in 19-28% of melanomas (56, 96, 135) , and, similarly to the BRAF p.V600E mutation, it is found early in melanomagenesis and maintained into metastasis (97) . The mutation at this codon prevents Ras GTPases from inactivating NRas, thus maintaining it in its active form and keeping both the MAPK and PI3K pathways constitutively active (8, 31) . Transfection of this mutation into cell lines has transforming abilities (99) . Importantly, the BRAF and NRas mutations in melanoma are mutually exclusive, illustrating the importance of this pathway (56, 78, 97) .
Although this review focuses on cutaneous malignant melanoma, it is worth noting that uveal melanomas lack both BRAF and NRas mutations (29) . Instead, these melanomas are associated with a recurrent mutation in GNAQ and its paralog GNA11 that also results in increased MAPK signaling; this mutation is a glutamine-to-leucine change at position 209 (p.Q209L) that results in a constitutively active form of GNAQ/GNA11. GNAQ and GNA11 mutations demonstrate mutual exclusivity, and both are frequent among uveal melanomas, with up to 77% of primary uveal melanomas having mutations in one of these genes (133, 134) .
KIT
c-KIT is a receptor tyrosine kinase that acts as a receptor for stem cell factor (SCF) ligand, and c-KIT-SCF signaling is required for melanocytic development (41, 58) . Although the initial reports regarding the role of c-KIT in melanoma were somewhat conflicting, analysis of a large melanoma cohort identified c-KIT amplifications in 6-8% of different melanoma subtypes, and somatic mutations were identified in mucosal, acral, and sun-damaged skin at frequencies of 21%, 11%, and 17%, respectively (30, 31) . Functional analysis of two of the c-KIT mutations, p.L576P and p.K642E, demonstrated increased activation of the PI3K pathway in normoxic conditions and of the RAS-RAF-MEK-ERK-MAPK pathway in hypoxic conditions (90) . Some moderate success has been seen with the use of the receptor kinase inhibitor Gleevec (imatinib) in metastatic melanoma patients with c-KIT mutations (22, 61) .
MITF and SOX10
The use of genome-wide SNP arrays and gene expression signatures identified amplifications in MITF in melanoma patients (45) . MITF is considered a master regulator of melanocytes, controlling the transcription of genes involved in melanocyte proliferation, survival, and differentiation (68) . One study found that MITF amplification events are associated with worse clinical features, potentially including poorer survival, increased metastasis, and chemotherapeutic resistance (45) . This study also demonstrated that, in conjunction with the BRAF p.V600E mutation, MITF overexpression was able to transform human melanocytes.
The crucial role of MITF in melanocyte development and the discovery of MITF amplification events within melanoma patients led to the sequencing of MITF and its binding partner, SOX10, in melanoma patients. Approximately 20% of analyzed samples harbored somatic mutations in either MITF or SOX10; these mutations occurred in a mutually exclusive manner and were independent of MITF amplification events (28) . Analysis of primary and metastatic melanomas indicated that MITF mutation events are likely to occur before metastasis. Analysis of MITF mutations indicated increased transcriptional activity that resulted in increased activation of the downstream targets human dopachrome tautomerase and tyrosinase, both of which are involved in melanoma pigmentation and differentiation. As discussed above (see Germline Alterations), two subsequent studies have now identified a germline variant in MITF (p.E318K) that predisposes individuals to melanoma and/or RCC (11, 150) , further substantiating a role for MITF in melanomagenesis.
The PI3K-PTEN-AKT Pathway
The PI3K-PTEN-AKT signaling pathway is frequently altered in numerous cancers, including melanomas affecting multiple cellular processes, such as cell proliferation and survival (reviewed in 123). Disruption of this pathway in melanomas is due largely to aberrant PTEN expression. Although infrequently affected by somatic point mutations (84) , PTEN expression is frequently lost or reduced, often as a result of both focal deletions and larger deletions affecting chromosome 10q (9, 131, 132, 149) . Aberrant PTEN expression results in increased levels of activated AKT; indeed, increased AKT3 activity has been observed in 40-60% of melanomas either directly, as a result of AKT3 copy-number alteration, or indirectly, as a result of PTEN loss or haploinsufficiency (126) . Mutation analysis in breast, colorectal, and ovarian cancers identified a recurrent mutation, p.E17K, in AKT1 (21) . This led to the sequencing of AKT1, AKT2, and AKT3 across a large cohort of melanoma patient samples and cell lines, revealing infrequent levels of the p.E17K mutation in AKT1 and AKT3 (35) .
PTPRD
Protein tyrosine phosphatase, receptor type, D (PTPRD) was initially implicated in melanoma pathogenesis through genome-wide assessment of loss of heterozygosity and copy-number alterations across 79 melanoma cell lines. PTPRD was homozygously deleted in 9% of cases, and subsequent studies have identified somatic mutations in up to 12% of analyzed samples (122, 127) . Functional work in melanoma cells further suggested a tumor suppressor role for PTPRD in melanoma.
ERBB4
Early sequencing of 518 genes encoding protein kinases across multiple cancers, including melanomas, identified a large number of mutations (57) . Through analysis of conserved domains, driver mutations were predicted to fall within 120 of the genes analyzed (57) . Although the melanoma samples included in this study contained the second-highest mutation rate, only a small number of melanomas were included. This led Prickett et al. (111) to perform a comprehensive analysis of the tyrosine kinome across a larger cohort of 79 melanomas. Beginning by sequencing coding regions of the kinase domains throughout 86 tyrosine kinases, they found 19 genes harboring somatic mutations and selected these for full gene sequencing. Of these genes, ERBB4, FLT1, and PTK2B were the most frequently mutated, exhibiting mutations in 19%, 10%, and 10% of analyzed samples, respectively. ERBB4 mutant protein demonstrated increased kinase activity and increased AKT phosphorylation compared with the wild type. This protein was also able to transform NIH3T3 and melanoma cells, and studies of short-hairpin RNA (shRNA) suggested that ERBB4 mutations confer a growth advantage compared with the wild type. Furthermore, treatment of mutant ERBB4 cells with the pan-ERBB inhibitor lapatinib increased apoptosis compared with wild-type cells.
Subsequent studies have identified additional and recurrent mutations in ERBB4, including two alterations of the same residue (127) that have since been observed in three additional samples (N.K. Hayward, personal communication). As sample numbers have increased, it has become apparent that ERBB4 mutations demonstrate significant mutual exclusivity with BRAF mutations ( p > 0.02, Fisher's exact test) suggesting that ERBB4 alterations are likely to be potent drivers of melanoma (140) . Interestingly, one instance has been described where a patient demonstrating a BRAF mutation and resistance to BRAF inhibitors also harbored an ERBB4 mutation (139), providing further evidence that these two melanoma drivers may be acting as separate forces in the development of melanoma.
Metalloproteinases
Systematic screening of three metalloproteinase families-the MMP (matrix metalloproteinase), ADAM (a disintegrin and metalloproteinase), and ADAMTS (a disintegrin and metalloproteinase with thrombospondin motif) groups-identified further four novel driver genes in melanoma: MMP8, ADAM7, ADAM29, and ADAMTS18. Both the ADAMs and ADAMTSs are involved in processes that affect cell adhesion and migration, and somatic mutations in numerous gene family members have been described in various cancers (4, 33, 88, 107, 121, 137, 148) . Systematic screening of both families revealed that approximately 20% of analyzed samples harbored somatic mutations in ADAMTS18 (142) and that 12.7% and 15.2% of analyzed samples harbored somatic mutations in ADAM7 and ADAM29, respectively (141) . Biological characterization of selected mutations in ADAMTS18 and ADAM7 revealed decreased adhesion of mutant forms to extracellular matrix components, resulting in an increased migratory phenotype in mutant cells compared with the wild type (141, 142) . Furthermore, mouse xenograft models with an ADAMTS18 mutation had increased ulcerative lesions and micrometastases compared with the wild type (142) .
Screening of the 23 MMP family members showed that up to 6% of melanomas harbored mutations in MMP8 (100). The biological properties and mutational spectrum of MMP8 were consistent with a tumor suppressor role. Mutant MMP8 resulted in increased anchorageindependent growth compared with the wild type in culture and increased formation of micrometastases and ulcerative lesions when assessed in mice. Further substantiating a role for MMP8 in melanoma, subsequent studies have associated melanoma with polymorphisms in MMP8 (36) and mutations in MMP family members (107) .
The information gleaned from these candidate-gene studies has been useful in identifying novel driver genes in melanoma that provide insight into both the basic biology of melanoma and targets for treatment-most notably the BRAF p.V600E mutation but also ERBB4, which represents a very real target for therapy with lapatinib or (if able to be developed) a more specific ERBB4 inhibitor. However, a more comprehensive catalog of somatic variation events in melanoma is required to identify more candidates. It is also particularly important to screen large cohorts in order to identify recurrent mutations, which, because they are easily screened for in a clinical situation and are likely to result in an activation mutation, are generally more amenable to use as therapeutic targets. The emergence of next-generation sequencing technologies has allowed researchers to take a more comprehensive, unbiased look into melanoma genetics and to uncover a number of genes with clear implication in tumor progression.
The Glutamate Signaling Pathway
Exome sequencing of 14 melanomas and their matched normal samples identified the ionotropic glutamate receptor subunit GRIN2A as being highly mutated (143) . Initial screening showed that 6 of 14 samples harbored GRIN2A mutations, which after subsequent analysis scaled up to 34 mutations across 135 samples (25.2%). Recurrent mutations were identified at three residues of GRIN2A along with mutation clustering within two functional domains: the PBP1 iGluR NMDA NR2 domain and the NMDAR2 C domain. GRIN2A mutations have since been described in additional melanoma cohorts with similar frequency, and some recurrent mutations have been found (67, 92, 127) . Although specific functional consequences of GRIN2A mutations in melanoma have not been reported, it is relevant that GRIN2A is a member of the glutamate receptor superfamily, which was first implicated in melanoma genesis by a study of mice predisposed to melanoma (108) . In this study, insertional mutations in an intronic region of the GRM1 gene caused aberrant GRM1 expression. Generation of melanocyte-specific, ectopically expressing GRM1 transgenic lines further confirmed the role of GRM1 in melanoma formation. Furthermore, aberrant expression of GRM1 was identified within a melanoma patient sample set (108) . GRM1 was later shown to be sufficient in transforming melanocytes (120) .
GRM1 and GRIN2A are members of the two major glutamate receptor groups: metabotropic glutamate receptors and ionotropic glutamate receptors, designated mGluRs and iGluRs, respectively. mGluRs, or GRMs, are G-protein-coupled receptors that have been associated with malignant melanoma, glioma, colorectal cancer, and breast cancer through somatic mutations and aberrant expression (reviewed in 112). iGluRs form large multiprotein complexes that act as N-methyl-D-aspartate receptors (NMDARs) (of which GRIN2A is one), α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid receptors (AMPARs), or kainite receptors (KARs), all of which are ion channels. iGluRs have been associated with malignant melanoma, glioma, schizophrenia, and Alzheimer disease (reviewed in 112).
GRM3, another member of the mGluR family, has also been identified as highly mutated in melanoma (113) . This study identified GRM3 mutations in melanoma by using exon capture technologies to screen the 734 genes of the G-protein-coupled receptor family, finding 106 somatic mutations across 94 genes. GRM3 was one of the most highly mutated genes, and subsequent analysis of additional samples identified further alterations (bringing the overall frequency to 16%) and highlighted a hot-spot mutation, p.E870K, in four individuals. This particular alteration was also identified in a separate melanoma whole-exome study by Halaban and colleagues (77) , who also identified GRM3 as a significantly mutated gene in melanoma. Functional analysis of a subset of GRM3 mutations, including p.E870K, showed increased activation of MEK1/2 upon stimulation with the DCG-IV agonist accompanied by an increased migratory phenotype in culture. shRNA knockdown of GRM3 in mutant and wild-type cell lines showed a dependency on mutant GRM3 for the observed migratory phenotype, which was also seen in mice injected with stable GRM3 knockdown cells on a mutant or wild-type background (113) . Furthermore, mutant GRM3 lines were more sensitive to the MEK1/2 inhibitor AZD-6244, which resulted in increased cell death of mutant lines compared with wild-type lines.
In addition to GRIN2A, GRM1, and GRM3 associations with melanoma, GRM5 was recently found to induce melanoma in mice (27) . In this study, ectopic expression of GRM5 in melanocytes driven by the TRP1 melanocyte-specific promoter resulted in hyperpigmentation and increased tumor formation in more than 50% of founder mice and in 100% of progeny. Pathway analysis of genes identified by Wei et al. (143) found the glutamate signaling pathway to be significantly mutated. Also of note is that additional genes involved in the glutamate signaling pathway, including ERBB4, PTK2B, and PLCβ4, are somatically altered in melanoma (112) .
TRRAP
Using exome sequencing data to identify recurrent mutations, Wei et al. (143) found 10 genes harboring a recurrent mutation in 2 or more individuals (out of 14 whole exomes). After the BRAF p.V600E mutation, the most frequent recurrent mutation was a p.S722F change within the transformation/transcription domain-associated protein (TRRAP) gene sequence. Subsequent prevalence screening showed that 6 separate melanomas out of 167 analyzed samples harbored this mutation (143) . The mutation has transforming ability, and cell lines harboring endogenous mutant TR-RAP are dependent on this for survival (143) . This mutation has now been seen in at least three additional cohorts (92, 127 ; P. Meltzer, personal communication).
MAPK Effectors
Two recent melanoma exome sequencing studies identified somatic mutations in MAP2K1 and MAP2K2 (92) and in MAP3K5 and MAP3K9 (127) . Nikolaev et al. (92) performed whole-exome sequencing of seven metastases from cutaneous malignant melanoma cases, including tumors excised from the same patient 12 years apart. The authors took a comprehensive approach and integrated their data with copy-number data obtained for the same samples, identifying the RAS-MAPK pathway as being frequently affected. Two tumors were identified that contained mutations in MAP2K1 (a.k.a. MEK1) and MAP2K2 (a.k.a. MEK2). A further prevalence screen of 120 tumors revealed additional mutations in these two genes, and in total, 10 mutations were found in either MAP2K1 or MAP2K2 across 127 samples. In addition, MAP2K1 was found to harbor two recurrent mutations: p.E203K (two cases) and p.P124S (four cases). Functional analysis of these two mutations demonstrated transforming ability and revealed them to be constitutively active, resulting in continued phosphorylation of ERK1/2. Importantly, further experiments showed that mutations in MAP2K1 and MAP2K2 confer an increased resistance to MEK inhibitors.
Whole-exome sequencing of eight cutaneous malignant melanoma cell lines and their matched normal samples coupled with subsequent prevalence screening of a large melanoma cohort found that MAP3K5 and MAP3K9 were mutated in 9% and 15% of all analyzed samples, respectively (127) . Mutations in these genes were mutually exclusive, and both genes resided in regions with focal areas of loss of heterozygosity. Three-dimensional models of MAP3K5 and MAP3K9 revealed several mutations that could potentially have an effect on protein structure, and these mutations were later functionally assessed. An in vitro kinase assay using cDNA constructs of two MAP3K5 mutations (p.E663K and p.L780F), a MAP3K9 mutation (p.Y333X), and a previously reported MAK3K9 kinase-dead mutation (p.K171A) revealed decreased phosphorylation activity of all mutants. As a result, expression of MAP3K5 mutants led to reduced JNK and MEK1/2 phosphorylation, and expression of MAP3K9 mutants led to decreased signaling through MAP2K4-MAP2K27, JNK, MEK1/2, and ERK. Furthermore, small interfering RNA (siRNA)-induced reduction of MAP3K9 expression in cells treated with the chemotherapeutic agent temozolomide resulted in increased viability when compared with cells treated with temozolomide alone, suggesting a therapeutic relevance of reactivation of MAP3K9/MAPK3K5 signaling pathways.
PREX2
Berger et al. (9) recently sequenced the whole genomes of 25 metastatic melanomas and their matched normal blood. This study showed a variable mutation rate depending on the location of the primary tumors, with acral tumors having significantly lower rates than trunk tumors. To identify significantly mutated genes, the authors took into account the number of mutations per gene, gene length, and the background mutation rate to generate a false-discovery-rate-adjusted p value (Q value). This analysis yielded 11 genes, with BRAF and NRas being the most significant. Another significantly mutated gene was phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 2 (PREX2), and four samples harbored truncating PREX2 mutations. A detailed analysis of PREX2 revealed that it contained numerous aberrations across several samples, including mutations, rearrangements, and amplification, suggesting a pathogenic role in melanoma. Subsequent sequencing on an additional panel of 107 samples revealed that PREX2 harbored nonsynonymous mutations in 14% of analyzed samples. Mouse xenograft studies demonstrated the functional significance of PREX2 mutations, showing accelerated tumorigenesis in mutant models when compared with wild-type or GFP controls and thereby confirming PREX2 as a melanoma driver.
Illustrating one of the benefits of whole-genome sequencing, the authors were also able to look for chromosomal rearrangements within their samples, and they found numerous sites affected by rearrangements. Interestingly, they identified four tumors with a rearrangement in the 5 untranslated region of A2BP1, which encodes an RNA-binding protein whose disruption has been linked to several neurodegenerative diseases.
RAC1
Two large studies recently published by Krauthammer et al. (77) and Hodis et al. (67) described whole-exome sequencing of 147 metastatic melanoma samples and 121 metastatic melanoma samples, respectively. Both studies identified a frequent recurrent mutation in RAC1, specifically a proline-to-serine change at position 29 (p.P29S) in both sample sets. Both groups determined that this mutation would confer a structural change that would favor the formation of a RAC1 active GTP-bound state, and then confirmed this: Because an active GTP-bound RAC1 binds the p21-binding domain (PBD) of p21-activated protein kinase (PAK1), a PAK1-PBD pull-down was used to show a greater complex formation with the mutant RAC1 compared with the wild type (67, 77) . Transfection of normal mouse melanocytes with either mutant or wild-type RAC1 showed that expression of mutant but not wild-type RAC1 led to increased ERK phosphorylation, increased cell migration, and increased proliferation (77) .
In addition to identifying the RAC1 recurrent mutation, both studies used the exome data from these large cohorts to identify significantly mutated genes. Whereas previous studies have taken into account a global background mutation rate, Hodis et al. (67) used a novel approach that www.annualreviews.org • The Genetics of Melanomautilized mutations captured in noncoding regions around each gene to determine locus-specific background mutation rates while controlling for variability in mutation rates found throughout the genome. This method generated a list of highly mutated genes, including six known cancer genes and five novel candidates, the latter of which were PPP6C, RAC1 (discussed above), SNX31, TACC1, and STK19. Krauthammer et al. (77) also found PPP6C to be highly mutated. The PPP6C mutations found by both groups cluster within a 12-amino-acid region located in a highly conserved catalytic subunit (67, 77) . Hodis et al. (67) found that PPP6C harbored a mutation in 9% of analyzed melanomas, with the majority of these mutations falling in the catalytic region; one of these mutations (p.R264C) was recurrent and represented at a frequency of 3% in an additional panel of 63 melanoma tumors (67) . STK19 also harbored a recurrent mutation (p.D89N) in addition to a mutation in the adjacent amino acid (p.P90L) (67) . An extension set of samples revealed that the p.D89N mutation was present in 5% of samples tested. Functional work is still needed to elucidate the effects of these mutations on melanoma tumorigenesis.
The authors of both papers observed that ARID2 contained a higher-than-expected number of loss-of-function mutations, i.e., nonsense, splice-site, and frameshift mutations (67, 77) . As ARID2 is a member of the SWI/SNF complex, Hodis et al. (67) performed a search of other members of this complex and found additional nonsense mutations in ARID1B, ARID1A, and SMARCA4 (67) . In total, 16 of the 121 samples surveyed by Hodis et al. (67) contained a mutation in one of the components of the SWI/SNF complex, indicating that a disruption of the chromatin remodeling complex may play a role in melanoma tumorigenesis (67, 77) .
Owing to the large cohort sizes in both studies, a subset of samples contained the wild type of both BRAF and NRas, and both studies found NF1 to be significantly mutated in these samples. They identified loss-of-function mutations in 25% (67) and 30% (77) of the analyzed samples, respectively. These mutations suggest that the BRAF/NRas wild-type samples are driven in a MAPK-pathway-independent manner (67, 77) .
PERSPECTIVES
Numerous genes have been implicated in melanoma pathogenesis at the germline and somatic levels, providing insight into melanoma biology and contributing to improved treatment options. However, there are known loci associated with the inheritance of melanoma susceptibility that have not led to gene discovery, and novel somatically altered genes continue to be identified in rapid succession. The use of exome/genome sequencing will help identify further candidates and has already made a large impact in identifying somatic alterations. Large sample sizes will be necessary to obtain the most information from these studies, as will assessment of biological functions using stringent methods, particularly in distinguishing between driver and passenger mutations in somatic situations. Future studies that take advantage of technological improvements should continue to increase germline and somatic gene discovery in melanoma and should open up new avenues for understanding melanoma pathogenesis as well as new opportunities for treatment.
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